Tempus CEO Eric Lefkofsky recently spoke about data-driven medicine and how it can help in taking care of cancer patients. In an interview posted online, he sought to explain the advantages of the new method and how Tempus is helping to make it work. His talk showed the volume of work that his staffs have invested in ensuring that the industry has better ways of diagnosing cancer. Here are the key points from his interview.
Mining patient records
According to the CEO, the biggest advantage of using data driven medicine is that it will be used to mine patient records. He is of the view that although there are many cancer patients in the world, their records are not properly documented. This makes it difficult for scientists to carry out thorough research that will lead to more innovations. However, when the records can be accessed without having to take too long, there is no doubt that every patient will get the right therapies regardless of where they live.
When sequencing cancer patients, the CEO says, the biggest challenge arises when sequencing them. There are millions of cancer patients in the world, but very few have been studied. In fact, the number whose information is wholly known is too small a specimen to be used for any conclusive research. So what are we supposed to do? Eric Lefkofsky says that he has the answer, and this lies in the use of data-driven medicine such as the one that is suggested by Tempus.
In addition to mining patient records, the CEO explained that this new method is likely to bring the cost of treating the disease down. Although he says that people will gain in many ways including an improvement in the quality of health services, he did not fail to mention that the costs will plummet once the method is fully operational.
A few facts about Eric Lefkofsky
Eric cofounded Tempus and serves as the company’s CEO. The company provides technology based medical solutions. He also helped to start Light Bank which specializes in the development of disruptive technologies. His education saw him attend the University of Michigan and University of Chicago.